---
title: "Ceribell wins CMS NTAP for delirium monitor, worth up to $2,171 per Medicare case"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294682766.md"
description: "Ceribell secured a CMS New Technology Add-on Payment (NTAP) for its Delirium Monitor System, allowing up to $2,171 per eligible Medicare inpatient case. This payment under the IPPS takes effect on October 1, 2026, enhancing hospital reimbursement economics. The decision follows FDA 510(k) clearance in December 2025, positioning Ceribell as the sole FDA-cleared aid for delirium screening."
datetime: "2026-08-03T11:03:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294682766.md)
  - [en](https://longbridge.com/en/news/294682766.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294682766.md)
---

# Ceribell wins CMS NTAP for delirium monitor, worth up to $2,171 per Medicare case

-   Ceribell won a CMS New Technology Add-on Payment for up to USD 2,171 per eligible Medicare inpatient case using its Delirium Monitor System. \* Payment add-on under Medicare’s IPPS takes effect Oct. 1, 2026, improving hospital reimbursement economics for the new monitoring service. \* Decision follows FDA 510(k) clearance in December 2025 for the delirium device, positioning it as the only FDA-cleared aid for delirium screening. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ceribell Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802205) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CBLL.US](https://longbridge.com/en/quote/CBLL.US.md)

## Related News & Research

- [Ceribell files Form 3 initial beneficial ownership statement for director Sharon O’Keefe](https://longbridge.com/en/news/294427776.md)
- [CMS grants NTAP reimbursement status for Abeona gene therapy ZEVASKYN under FY2027 IPPS rule](https://longbridge.com/en/news/294816144.md)
- [11:15 ETAn InventHelp 123Invent Client Develops a Hiking Support Aid for Improved Mobility (LBT-9828)](https://longbridge.com/en/news/294844893.md)
- [CMS finalizes new Medicare DRG reimbursement codes for Carlsmed aprevo lumbar fusion procedures](https://longbridge.com/en/news/294692142.md)
- [Top Executive Doubles Down on CMS Energy With Fresh Insider Buy](https://longbridge.com/en/news/294764975.md)